| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/11/2001 | US6287802 EXT2 gene |
| 09/11/2001 | US6287794 Peptide having antithrombotic effect through reversible inhibition of blood coagulation factor; antiinflammatory agents; treatment of cardiovascular disorders |
| 09/11/2001 | US6287759 Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
| 09/11/2001 | US6287757 Amino acid-trehalose composition |
| 09/11/2001 | US6287601 Equine laminitis |
| 09/11/2001 | US6287574 Proteinase K resistant surface protein of neisseria meningitidis |
| 09/11/2001 | US6287557 Methods of gene therapy using herpes viral vectors expressing GM-CSF |
| 09/11/2001 | CA2230936C 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists |
| 09/11/2001 | CA2195119C Formulations and methods for providing prolonged local anesthesia |
| 09/11/2001 | CA2176205C Osteogenic product and process |
| 09/11/2001 | CA2087091C Excitatory amino acid antagonists |
| 09/11/2001 | CA2057578C 1,4-disubstituted piperazines, process for their preparation and pharmaceutical compositions containing them |
| 09/11/2001 | CA2037099C Crystalline salt of 4-(di-n-propyl) amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz ¢cd! indole |
| 09/11/2001 | CA2031570C Substituted cyclohexenes as central nervous system agents |
| 09/11/2001 | CA2023194C Peptides having bradykinin antagonist action |
| 09/07/2001 | WO2001064956A2 The identification and use of effectors and allosteric molecules for the alteration of gene expression |
| 09/07/2001 | WO2001064943A1 Method of screening substance specifically inhibiting non-mevalonate pathway |
| 09/07/2001 | WO2001064930A1 Protein hollow nano particles, transporter with the use of the same and method of introducing substance into cells |
| 09/07/2001 | WO2001064907A2 Lipid metabolism enzymes |
| 09/07/2001 | WO2001064896A2 Human enzyme molecules |
| 09/07/2001 | WO2001064885A1 Chordin-like-2 molecules and uses thereof |
| 09/07/2001 | WO2001064884A2 G12l, a gene associated with the thermal response |
| 09/07/2001 | WO2001064870A2 Mutated cyclin g1 protein |
| 09/07/2001 | WO2001064862A1 Human monoclonal antibodies against oxidized ldl receptor and medicinal use thereof |
| 09/07/2001 | WO2001064755A2 Isoxazole gegen virale erkrankungen |
| 09/07/2001 | WO2001064741A2 Methods for selectively modulating survivin apoptosis pathways |
| 09/07/2001 | WO2001064737A1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 09/07/2001 | WO2001064703A1 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/07/2001 | WO2001064692A1 Cardioprotective phosphonates and malonates |
| 09/07/2001 | WO2001064687A1 Anti-infective ecta?tm¿ |
| 09/07/2001 | WO2001064685A2 Thienopyridine derivatives and their use as anti-inflammatory agents |
| 09/07/2001 | WO2001064681A2 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | WO2001064678A2 Inhibitors of hepatitis c virus ns3 protease |
| 09/07/2001 | WO2001064674A1 2,4-disubstituted thiazolyl derivatives |
| 09/07/2001 | WO2001064670A1 Novel cyclic amide derivatives |
| 09/07/2001 | WO2001064666A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | WO2001064661A1 Antioxidants |
| 09/07/2001 | WO2001064656A1 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064655A1 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | WO2001064654A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064653A1 Pyrimidine compounds |
| 09/07/2001 | WO2001064650A2 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 09/07/2001 | WO2001064645A2 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | WO2001064639A2 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | WO2001064635A1 Ningalin b analogs employable for reversing multidrug resistance |
| 09/07/2001 | WO2001064252A2 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 09/07/2001 | WO2001064251A2 Combination chemotherapy |
| 09/07/2001 | WO2001064250A1 Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| 09/07/2001 | WO2001064247A2 Method of treating cancer with anti-neurotrophin agents |
| 09/07/2001 | WO2001064240A2 Methods for promoting production of myelin by schwann cells |
| 09/07/2001 | WO2001064236A2 METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS |
| 09/07/2001 | WO2001064234A1 Casein derived peptides and uses thereof in therapy |
| 09/07/2001 | WO2001064226A2 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 09/07/2001 | WO2001064217A2 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 09/07/2001 | WO2001064215A1 Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis |
| 09/07/2001 | WO2001064214A2 Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
| 09/07/2001 | WO2001064208A1 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064200A2 Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy |
| 09/07/2001 | WO2001064199A2 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 09/07/2001 | WO2001064198A2 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 09/07/2001 | WO2001064197A2 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 09/07/2001 | WO2001064195A2 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 09/07/2001 | WO2001064194A2 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 09/07/2001 | WO2001064165A2 Il-8 receptor antagonists |
| 09/07/2001 | WO2001064163A2 An improved herbal composition having antiallergic properties and a process for the preparation thereof |
| 09/07/2001 | WO2001064046A2 Method for isolating sponge collagen and producing nanoparticulate collagen, and the use thereof |
| 09/07/2001 | WO2001064008A2 Vaccine for the treatment of artherosclerosis |
| 09/07/2001 | WO2001043747A8 Matrix tablet for prolonged release of trimetazidine after oral administration |
| 09/07/2001 | WO2001032898A3 Recombinant sendai virus vector for introducing exogenous genes to airway epithelia |
| 09/07/2001 | WO2001022923A3 Scar treatment composition |
| 09/07/2001 | WO2001021761A3 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 09/07/2001 | WO2001016289A3 Zymogen activation system |
| 09/07/2001 | WO2001016135A3 Reverse-turn mimetics and methods relating thereto |
| 09/07/2001 | WO2001013901A3 A pharmaceutical delivery system for vitamin c and vitamin e and use of a combination of vitamin c and e for preventing or treating conditions involving oxidative stress |
| 09/07/2001 | WO2001012812A3 Baff receptor (bcma), an immunoregulatory agent |
| 09/07/2001 | WO2001010383A3 Caspase inhibitors and uses thereof |
| 09/07/2001 | WO2001005823A3 Tryptase inhibitor |
| 09/07/2001 | WO2001000197A3 Methods of treating fungal infections with inhibitors of nad synthetase enzyme |
| 09/07/2001 | WO2000075107A3 Bradykinin receptor antagonists |
| 09/07/2001 | WO2000071571A3 Fap-activated anti-tumor compounds |
| 09/07/2001 | WO2000047618A3 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES |
| 09/07/2001 | WO2000046389A9 Process for the preparation of pseudomonic acid a antibiotic by microbiological method |
| 09/07/2001 | CA2401993A1 Human monoclonal antibodies against oxidized ldl receptor and pharmaceutical uses thereof |
| 09/07/2001 | CA2401800A1 Synthesis of epothilones, intermediates thereto and analogues thereof |
| 09/07/2001 | CA2401755A1 Vaccine for the treatment of artherosclerosis |
| 09/07/2001 | CA2401716A1 Methods for promoting production of myelin by schwann cells |
| 09/07/2001 | CA2401673A1 Ningalin b analogs employable for reversing multidrug resistance |
| 09/07/2001 | CA2401670A1 Human enzyme molecules |
| 09/07/2001 | CA2401667A1 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 09/07/2001 | CA2401660A1 Lipid metabolism enzymes |
| 09/07/2001 | CA2401659A1 Il-8 receptor antagonists |
| 09/07/2001 | CA2401654A1 The identification and use of effectors and allosteric molecules for the alteration of gene expression |
| 09/07/2001 | CA2401607A1 Methods for selectively modulating survivin apoptosis pathways |
| 09/07/2001 | CA2401550A1 Casein derived peptides and uses thereof in therapy |
| 09/07/2001 | CA2401489A1 Oxygen-containing heterocyclic compounds |
| 09/07/2001 | CA2401405A1 Medicament for viral diseases |
| 09/07/2001 | CA2401340A1 Compositions and methods for the treatment of inflammatory disease using topoisomerase inhibitors |
| 09/07/2001 | CA2401304A1 Combination chemotherapy |
| 09/07/2001 | CA2401175A1 Chordin-like-2 molecules and uses thereof |
| 09/07/2001 | CA2401173A1 G12l, a gene associated with the thermal response |